← board
ASRT
distress 0/10 · well-funded / low risk$23.500%today0% from 52w high
Revenue
pre-revenue
Liquidity
$72M
Runway
10.2 yrs
Shares 1y
-93%
Price & events
+101.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.3%
1M
+21.2%
3M
+146.6%
6M
+141.4%
1Y
—
2Y
—
5Y
+84.3%
All
Overview
- Market Cap
- $151.86M
- Enterprise Value
- $157.40M
- Volume
- 0
- 52 Week Range
- $9.07 – $23.50
- Total Shares
- 6.46M
- Float Shares
- 6.26M
- Short %
- 5.25%
- % Held by Insiders
- 1.97%
- % Held by Institutions
- 29.29%
- Beta
- 0.53
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $24 (+4% upside) · 3 analysts
- 2026-05-13Lake StreetHold
- 2026-05-05HC Wainwright & Co.Neutral
- 2026-04-09Lake StreetBuy → Hold
- 2026-04-09HC Wainwright & Co.Buy → Neutral
- 2026-01-05HC Wainwright & Co.Buy
- 2025-08-12HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-16ASRT Museum and Archives launches self-guided video tour - AuntMinnie
- 2026-07-15Press Release: Assertio Provides Update on Garda Therapeutics Tender Process - Moomoo
- 2026-07-13Assertio Beats Investor Suit Over Drug, Merger Claims - Law360
- 2026-07-13Assertio Investors Fail to Advance Suit Over Spectrum Merger (1) - Bloomberg Law News
- 2026-07-10Assertio (ASRT) Small-Cap Growth Virtual Investor Conference Summary - Quartr
- 2026-07-10Assertio (ASRT) Proxy Filing Summary - Quartr
- 2026-07-08Assertio (ASRT) Maxim Group’s 2024 Healthcare Virtual Summit Summary - Quartr
- 2026-07-08Assertio (ASRT) Q1 2026 earnings summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.